The mice were immunized with 25 μg of OVA (chicken egg albumin, grade V, from Sigma-Aldrich, St. Louis, MO, USA) with 1 mg of aluminium hydroxide (alum) in 200 μL of phosphate-buffered saline (PBS). The mice were immunized by subcutaneous injection on days 0, 7, 14, and 21, and then challenged with intranasal OVA (20 μg/50 μL PBS) on day 33, 35, and 37 and then again twice a week for 3 months while anaesthetized with isoflurane (Vedco, St. Joseph, MO, USA). CON mice were treated with PBS in the same manner. Mice were killed 24 hours after the final OVA challenge, and bronchoalveolar lavage fluid (BALF) and lung tissues were obtained.
Ovalbumin (ova)
Manufactured by Vedco
Sourced in United States
The OVA is a laboratory equipment designed for the identification and analysis of ova (eggs) in various samples. It provides a standardized and efficient method for detecting the presence of ova in a sample, which is crucial for various applications such as parasitology and environmental monitoring.
Automatically generated - may contain errors
6 protocols using ovalbumin (ova)
1
Murine Model of Allergic Airway Inflammation
2
Chronic Intranasal Ovalbumin Challenge Model
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Mice were immunized by subcutaneous injection with 25 μg of OVA (Grade V; Sigma-Aldrich, St. Louis, MO, USA) adsorbed to 1 mg of aluminum hydroxide (Aldrich, Milwaukee, WI, USA) in 200 μL of phosphate-buffered saline (PBS). Subcutaneous injections were performed on days 0, 7, 14, and 21 and intranasal OVA challenge (20 μg/50 μL in PBS) was administered on days 27, 29, and 31 under isoflurane (Vedco, St. Joseph, MO, USA) anesthesia. Intranasal OVA challenges were then repeated twice per week for 3 months. Age- and gender-matched control mice were treated in the same way with PBS but without OVA. Mice were sacrificed 24 hours after the final OVA challenge, and bronchoalveolar lavage (BAL) fluid and lung tissues were obtained.
All procedures for animal research were performed in accordance with the Laboratory Animals Welfare Act, the Guide for the Care and Use of Laboratory Animals, and the Guidelines and Policies for Rodent Experiments provided by the Institutional Animal Care and Use Committee at the School of Medicine, The Catholic University of Korea.
All procedures for animal research were performed in accordance with the Laboratory Animals Welfare Act, the Guide for the Care and Use of Laboratory Animals, and the Guidelines and Policies for Rodent Experiments provided by the Institutional Animal Care and Use Committee at the School of Medicine, The Catholic University of Korea.
3
Murine Model of Allergic Asthma
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
The mice were immunized by subcutaneously injecting with 25 µg of OVA (grade V; Sigma-Aldrich, St. Louis, MO, USA) adsorbed to 1 mg of aluminum hydroxide (Aldrich, Milwaukee, WI, USA) in 200 µL of phosphate-buffered saline (PBS). The injections were administered on days 0, 7, 14, and 21. Intranasal challenge with 20 µg OVA/50 µL PBS was administered on days 27, 29, and 31 to mice under isoflurane (Vedco, St. Joseph, MO, USA) anesthesia. The intranasal OVA challenges were then repeated twice a week for 3 months. Age- and sex-matched control mice were treated identically but with PBS alone. All of the mice were euthanized 24 hours after the final OVA challenge, at which time bronchoalveolar lavage (BAL) fluid and lung tissues were obtained. All of the animal research procedures were conducted in accordance with the Laboratory Animals Welfare Act, the Guide for the Care and Use of Laboratory Animals, and the Guidelines and Policies for Rodent Experiments mandated by the Institutional Animal Care and Use Committee of the School of Medicine, The Catholic University of Korea.
4
Murine Model of Ovalbumin-Induced Asthma
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Mice were sensitized and challenged with OVA as previously described.15 (link) Sensitization was done by subcutaneous injection of OVA (Sigma-Aldrich, St. Louis, MO, USA) adsorbed to 1 mg of aluminum hydroxide (Aldrich, Milwaukee, WI, USA) in 200 μL of normal saline. After sensitization on days 1 and 8, challenges were done by intranasal inhalation of OVA (20 ng/50 μL in phosphate-buffered saline [PBS]) on days 21, 23, 25, and 28 under isoflurane (Vedco, St. Joseph, MO, USA) anesthesia. The control groups were treated in the same way with PBS without OVA. Mice were sacrificed 24 hours after the final OVA challenge after measuring AHR.
5
Murine Model of Allergic Airway Inflammation
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
OVA sensitization and challenge were performed as described previously23 (link). Mice were immunized via subcutaneous injection of 25 μg OVA (chicken egg albumin, grade V; Sigma-Aldrich, St. Louis, MO, USA) absorbed to 1 mg of aluminum hydroxide (Sigma-Aldrich, Milwaukee, WI, USA) in 200 μL of PBS. Injections were administered on days 0, 7, 14, and 21, followed by intranasal OVA (20 μg/50 μL in PBS) challenge on days 33, 35, and 37. The OVA challenge was repeated twice weekly for 3 months after the mice had been anaesthetized with isoflurane (Vedco, St. Joseph, MO, USA). Age- and sex-matched control mice received PBS without OVA. Mice were sacrificed 24 h after the last intranasal OVA challenge, and bronchoalveolar lavage (BAL) fluid and lung tissues were collected.
6
Murine Models of Asthma, COPD, and ACO
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Female C57BL/6N mice (Orient, Gyeongi-do, Korea) aged 6 weeks were used in this study. The mice were divided randomly into control, asthma, COPD, ACO-a, and ACO-b groups.
Mice in the asthma group were immunized with 50 μg OVA (chicken egg albumin, grade V; Sigma-Aldrich, St. Louis, MO, USA) in 1 mg aluminum hydroxide (Sigma-Aldrich) in 200 μL phosphate-buffered saline (PBS). Immunization was performed by intraperitoneal injection on days 0, 7, and 14, and intranasal OVA challenges (100 μg/50 μL PBS) were administered on days 21, 22, 23, and 24 under anesthesia with isoflurane (Vedco, St. Joseph, MO, USA). Mice in the COPD group received intratracheally administer PPE (80 U/kg; Elastin Products Company, Owensville, MI, USA) in 100 μL PBS on day 0. Mice in the ACO-a group received the treatments administered to the asthma (OVA) and COPD (PPE) groups. Mice in the ACO-b group were treated intratracheally with 50 μg papain (Sigma-Aldrich) in 100 μL PBS on days 0, 7, 14, and 21. PPE or papain aerosol was created using a Micro Sprayer Aerosolizer (Penn Century Inc., Wyndmoor, PA, USA). The animals were euthanized on day 25 (Fig.1 ).![]()
Mice in the asthma group were immunized with 50 μg OVA (chicken egg albumin, grade V; Sigma-Aldrich, St. Louis, MO, USA) in 1 mg aluminum hydroxide (Sigma-Aldrich) in 200 μL phosphate-buffered saline (PBS). Immunization was performed by intraperitoneal injection on days 0, 7, and 14, and intranasal OVA challenges (100 μg/50 μL PBS) were administered on days 21, 22, 23, and 24 under anesthesia with isoflurane (Vedco, St. Joseph, MO, USA). Mice in the COPD group received intratracheally administer PPE (80 U/kg; Elastin Products Company, Owensville, MI, USA) in 100 μL PBS on day 0. Mice in the ACO-a group received the treatments administered to the asthma (OVA) and COPD (PPE) groups. Mice in the ACO-b group were treated intratracheally with 50 μg papain (Sigma-Aldrich) in 100 μL PBS on days 0, 7, 14, and 21. PPE or papain aerosol was created using a Micro Sprayer Aerosolizer (Penn Century Inc., Wyndmoor, PA, USA). The animals were euthanized on day 25 (Fig.
Pulmonary disease models. ACO, asthma–chronic obstructive pulmonary disease overlap; alum, aluminum hydroxide; i.p., intraperitoneal; i.t., intratracheal; OVA, OVAlbumin; PPE, porcine pancreatic elastase
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!